ArticlePulmonary circulation2022
The evolution of survival of pulmonary arterial hypertension over 15 years.
Article in Pulmonary circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies.Respiratory research · 2024Pooled it
- Effects of Web-Based Symptom Monitoring Program on Symptom Interference, Physical Activity, and Emergency Department Readmissions in Patients With Pre-Capillary Pulmonary Hypertension: Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension.Advances in therapy · 2024Trial
- The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells.EBioMedicine · 2024Trial
- Food Effects on the Pharmacokinetics of Single Dose and Steady-State Ralinepag, a Novel Oral Prostacyclin Agonist, in Healthy Volunteers.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Article
- Trends and future projections of the disease burden of pulmonary arterial Hypertension-related heart failure in China and G20 countries: Based on the global burden of disease 2023 database.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Article
- Article
- Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies.Journal of market access & health policy · 2026Article
- Associations Between Right Ventricular Remodeling, Exercise and Circulating Metabolites in Volume and Pressure Overload States.JACC. Asia · 2026Article
- Morning Larks and Night Owls: Considering Chronotype in Evaluation of Patients with Pulmonary Hypertension.Annals of the American Thoracic Society · 2026Article
- Performance on the one-minute sit-to-stand test predicts long-term adverse outcomes in pulmonary hypertension.Scientific reports · 2026Article
- Article
- Endothelial glycosylation and its emerging role in pulmonary vascular health and disease.Nature communications · 2025Review
- [Neuraxial anesthesia procedures in the perioperative management of pulmonary hypertension : A literature review with two case reports].Die Anaesthesiologie · 2025Review
- Identification of Diagnostic Biomarkers Causally Associated With Gut Microbiota and Pulmonary Arterial Hypertension.Pulmonary circulation · 2025Article
- A structured approach for identifying disease analogs for pulmonary arterial hypertension.Journal of managed care & specialty pharmacy · 2025Article
- Safety and pharmacokinetics of ralinepag, a novel oral prostacyclin receptor agonist.JHLT open · 2025Article
- Winning With Four: Hemodynamic and Symptomatic Improvement of Pulmonary Arterial Hypertension With Contemporary Quadruple Therapy.JACC. Case reports · 2025Article
- Integrated bioinformatics identifies ferroptosis biomarkers and therapeutic targets in idiopathic pulmonary arterial hypertension.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of pulmonary arterial hypertension (PAH) remains dismal. Over the years, multiple therapeutic advances have been introduced. This study evaluates the evolution of PAH survival over the past 15 years. We included 293 consecutive adult patients diagnosed with PAH between 2005 and 2019 (median age: 61.8 years, 70.3% female). Patients were divided into three cohorts based on the time of diagnosis: 2005-2009, 2010-2014, and 2015-2019 (2005-2009:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.